Crossmark

A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma

Crossref DOI link: https://doi.org/10.1186/s12885-021-07877-7

Published Online: 2021-02-16

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Paiella, Salvatore

Malleo, Giuseppe

Simoni, Nicola

Micera, Renato

Guariglia, Stefania

Cavedon, Carlo

Marchegiani, Giovanni

Esposito, Alessandro

Landoni, Luca

Casetti, Luca

Tuveri, Massimiliano

Milella, Michele

Secchettin, Erica

Manzini, Gessica

Bovo, Chiara

De Pastena, Matteo

Fontana, Martina

Salvia, Roberto

Mazzarotto, Renzo

Bassi, Claudio
License Information

Text and Data Mining valid from 2021-02-16

Version of Record valid from 2021-02-16
More Information

Article History

Received: 13 April 2020

Accepted: 4 February 2021

First Online: 16 February 2021

Ethics approval and consent to participate

: the protocol obtained the approval of the local Ethics Committee (#2301CESC, Ethics Committee of Verona and Rovigo provinces, University Hospital of Verona) and patients enrolled will sign an informed consent.

: not applicable.

: none.

Document is current

Any future updates will be listed below